Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
esketamine + dexmedetomidine (Peking University Shenzhen Hospital)
- Development stage
- Unknown
- Lead developer
- Peking University Shenzhen Hospital
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Esketamine + dexmedetomidine is a drug combination being evaluated by Peking University Shenzhen Hospital for its effects on postoperative sleep quality, pain management, and cognitive function in elderly patients undergoing hip fracture surgery. Esketamine, the S-enantiomer of ketamine, functions as a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, providing potent analgesia and anesthetic effects. Dexmedetomidine is a highly selective alpha-2 adrenergic receptor agonist known for its sedative, analgesic, and sympatholytic properties without causing significant respiratory depression. The combination is administered intravenously via a loading dose followed by a continuous infusion to leverage the synergistic effects of both agents while potentially reducing the required dosage and side effect profile of each component.
- Other names
- esketamine combined with dexmedetomidine
02
Targets
DOR (Opioid Receptor Delta 1)SERT (Sodium-dependent serotonin transporter)NMDAR (Glutamate receptor ionotropic, NMDA)HTR3A (5-hydroxytryptamine receptor 3A)KOR (Kappa opioid receptor)ADRA2A (α2A)DAT (Dopamine plasma membrane transport protein)MOR (Mu opioid receptor)DRD2 (Dopamine D2 Receptor)NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on esketamine + dexmedetomidine (Peking University Shenzhen Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on esketamine + dexmedetomidine (Peking University Shenzhen Hospital).